DrugPatentWatch Database Preview
Abbvie Inc Company Profile
What is the competitive landscape for ABBVIE INC, and what generic alternatives to ABBVIE INC drugs are available?
ABBVIE INC has nine approved drugs.
There are forty US patents protecting ABBVIE INC drugs.
There are seven hundred and fifty patent family members on ABBVIE INC drugs in fifty-three countries and eighty-three supplementary protection certificates in sixteen countries.
Summary for Abbvie Inc
| International Patents: | 750 |
| US Patents: | 40 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 9 |
| Drug Master File Entries: | 15 |
| Patent Litigation for Abbvie Inc: | See patent lawsuits for Abbvie Inc |
Drugs and US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | RX | Yes | Yes | 8,686,026 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | RX | Yes | Yes | 9,629,841 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Abbvie Inc | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 7,041,319 | ➤ Sign Up |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 6,277,405 | ➤ Sign Up |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 6,589,552 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
| ➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
International Patents for Abbvie Inc Drugs
Supplementary Protection Certificates for Abbvie Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2368890 | 2015/010 | Ireland | ➤ Sign Up | PRODUCT NAME: OMBITASVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
| 2203431 | 247 50008-2015 | Slovakia | ➤ Sign Up | PRODUCT NAME: DASABUVIR (VO FORME MONOHYDRATU SODNEJ SOLI); REGISTRATION NO/DATE: EU/1/14/983/001 20150119 |
| 2340029 | 32/2015 | Austria | ➤ Sign Up | PRODUCT NAME: PARITAPREVIR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER ANNEHMBARER ESTER DAVON; REGISTRATION NO/DATE: (MITTEILUNG VOM 19.1.2015) EU/1/14/982 20150115 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
